Life Sciences Consultancy
Science
Strategy
Growth
Empowering life sciences companies to turn innovation into lasting enterprise value.
Our mission is to help life sciences companies turn scientific innovation into real business value achieving sustainable growth through strategic alignment, capital access, strong partnerships, and effective transformation initiatives.
About us
At Accelero, we believe that great science deserves the chance to become great business. That’s why we work with life sciences companies to turn innovation into lasting enterprise value.
We guide life science companies through their entire journey from early strategic design and investor engagement to market readiness and organisational transformation.
Through strategic guidance, access to capital, strong partnerships, and transformation support, we help our clients build the capabilities for sustainable growth.
Our experience spans transactions totalling several hundred million euros and a wide range of partnerships and transformations across the life sciences sector.
All driven by one goal: to turn potential into tangible results, ensuring that our clients can grow with confidence and achieve sustainable success.
From pre-clinical to commercial, we connect science with strategy, capital, partner, and organisational readiness to bring innovation to market.
Strategy and Decision Architecture
Translating scientific ambition into strategic direction!
We align research priorities, development milestones, and market potential to design clear, data-driven roadmaps. This will guide decision-making across the pre-clinical, clinical, and growth phases.
Focus
-
Portfolio strategy
-
rNPV & scenario modeling
-
Business model design
-
Commercialisation & exit planning
Commercialisation and Market Access
Turning innovation into patient and market value
As products approach commercialisation, we develop pricing, reimbursement, and evidence strategies that achieve payer confidence and sustainable market access.
Focus
-
Pricing & Reimbursement
-
Health economics & outcomes research
-
Launch planning
-
Revenue forecasting
Investor Access and Licensing
Connecting science with capital, and the right partners!
Beyond introductions to our investor network, we actively support licensing activities by using our pharma contacts to identify, evaluate, and structure collaborations that drive long-term value.
Focus
-
Capital roadmap
-
Investor introductions
-
Licensing matchmaking
-
Valuation and deal support
-
Investment readiness
Transformation, Integration and Organisational Growth
Building the company behind the science an helping it grow through change.
Our transformation programs prepare leadership teams for scale and guide them through post-merger or organisationalchange. This will ensure continuity, alignment, and sustainable performance.
Focus
-
Governance & readiness
-
Cultural change
-
M&A integration plannin
-
Process guidance & optimisation
-
Scale up management
Accelero Insights
10
Years of Operations
> € 800m
In transactions advised
25+
Partnering Transactions
15+
Transformation facilitated
Meet Our Team
Detlef Krawinkel
As CEO and Founder Detlef brings over a decade of experience guiding biotech and medtech leaders through critical growth phases. He specializes in strategy, capital access, and board-level advisory.
Dr. Barbara Troup
Barbara is an expert on organizational change and leadership communication. She supports life science companies in navigating transformation with clarity and impact.
Dr. Peter Stagier
Peter combines financial acumen with deep capital raising expertise and forecasting. He advises on cost-effective scale-up and investment planning for life science companies.
Edward Gudaitis
Edward is a seasoned commercial strategist with a track record in biotech and pharma. He guides clients in building competitive go-to-market strategies and securing licensing deals.
Bertrand Bonnot
Bertrand has extensive experience in market entry and international business development. He helps innovators unlock new geographies and build sustainable partnerships.
Ruben Giorgino
Ruben brings extensive experience in pre-clinical clinical development across pharma and rare diseases. He supports companies in advancing therapies from research through clinical trials, ensuring scientific rigor and regulatory alignment.
Dr. Peter Schiemann
Peter brings decades of experience in product manufacturing and global labeling compliance. He supports companies in delivering reliable, regulatory-compliant products worldwide.
Beat
Widler
Beat is a recognized specialist in regulatory affairs, quality management, and pharmacovigilance. He ensures clients meet compliance standards while accelerating approvals.
Client Stories
A European biotech lacked clarity on strategy, clinical and fundraising priorities. Accelero aligned leadership with a 24-month roadmap, connected with its investor network, enabling a €20M capital raise and a strategic US pharma co-development deal.
CEO Rare Disease Company
A European company struggled to secure investors or partners. Accelero reframed its strategy, refined the value proposition and outreached into the market while activating its global networks, leading to a $15M Series A Capital Raise.
CEO Cellular Medicine
A European biotech was seeking the right partner to advance its breakthrough therapy. Accelero reshaped the partnering strategy, and leveraged its global network, leading to a licensing agreement with a leading pharma company. The deal secured a double-digit million first milestone alongside highly attractive royalty payments.
CEO Longevity Company
Partnerships
Ready to take your innovation from science to scale, and beyond integration? Let us explore how strategy, capital and transformation can accelerate your next phase of growth.